Emerging Company Profile
Asher Bio: aiming cytokine therapies at specific immune cells
Emerging Company Profile: Asher Bio engineering cytokine specificity with Third Rock-led $55 million series A
Asher Biotherapeutics launches with a Third Rock-led $55 million series A and a platform to improve the safety and efficacy of cytokines by requiring binding to two targets on a single immune cell.
Mar 25, 2021 | 11:06 PM GMT
Asher Bio emerged from stealth Tuesday with